Search Within

Genitourinary Oncology Service

  1. "Oncology Nursing Society (ONS)"
Formats
  1. Meeting Abstract (5)
Groups
  1. Department of Medicine (5)
  2. Solid Tumor Oncology Division (5)
  3. Advanced Practice Providers (1)
  4. Nursing (1)
People
  1. Dana Rathkopf (4)
  2. Catherine Cullum (1)
  3. Celine Nguyen (1)
  4. Meagan McQuade (1)
  5. Melanie Melendez (1)
  6. Robert Motzer (1)
Years
  1. 2024 (2)
  2. 2023 (2)
  3. 2017 (1)
Publications
  1. Oncology Nursing Forum (5)
Publishers
  1. Oncology Nursing Society (ONS) (5)

Results (5)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Patient-reported outcomes in patients with metastatic castration-resistant prostate cancer and BRCA1/2 mutations receiving first-line niraparib with abiraterone acetate plus prednisone (Magnitude study)
    Meeting Abstract

    Nguyen, C.; Rathkopf, D. E.; Chi, K. N.; Small, E.; Smith, M.
    Oncology Nursing Forum (2024)

    Fulltext@MSK | Save
  • Final analysis of patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations receiving first-line niraparib with abiraterone acetate plus prednisone (MAGNITUDE Study) for cancer caregivers: A pilot to address existential distress in caregivers of hematopoietic stem cell transplant patients
    Meeting Abstract

    Olivier, K.; Smith, M.; Rathkopf, D. E.; Small, E.; Guckert, M.; Chi, K. N.
    Oncology Nursing Forum (2024)

    Fulltext@MSK | Save
  • Phase 3 MAGNITUDE study: Results from second interim analysis of niraparib with abiraterone acetate and prednisone as first-line therapy in patients with metastatic castration-resistant prostate cancer with and without HRR gene alteration
    Meeting Abstract

    Rathkopf, D. E.; Small, E.; Guckert, M.; Chi, K. N.
    Oncology Nursing Forum (2023)

    Fulltext@MSK | Save
  • Patients receiving short run-in treatment (≤2 months) with abiraterone acetate and prednisone (AAP) showed similar benefit from niraparib and AAP in the phase 3 MAGNITUDE study with metastatic castration-resistant prostate cancer and HRR gene alterations
    Meeting Abstract

    Smith, M.; Efstathiou, E.; Rathkopf, D. E.; Guckert, M.; Chi, K. N.
    Oncology Nursing Forum (2023)

    Fulltext@MSK | Save
  • Decreasing catheter-associated urinary tract infections through changes in workflow
    Meeting Abstract

    McQuade, M.; Motzer, R.; McCormick, M.; Cullum, C.; Mayer, D. M.
    Oncology Nursing Forum (2017)

    Fulltext@MSK | Save